SOSV portfolio company and graduate of the IndieBio progrmam, Ten63 Therapeutics recently announced that it added strategic investment from new investors Chugai Venture Fund and the Gates Foundation, bringing the company’s total funding to over $45M.
The company is an advanced AI drug-discovery company and with this increased funding they plan to fuel the advancement of their proprietary computational drug discovery platform, BEYOND. BEYOND is the world’s first Large Quantum Chemistry Model (LQCM), delivering precise quantum-mechanics level simulations that are orders of magnitude faster than other cutting-edge computational approaches. BEYOND enables the pursuit of previously undruggable targets, which correspond to 80% of all proteins in the human body.
Check out our SOSV profile on how Ten63 turned an academic project into an AI platform for drugging “undruggable” cancers here. And read more about the fundraising: